Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
Children's Oncology Group
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Takeda
Incyte Corporation
National Cancer Institute (NCI)
Children's Oncology Group
Amgen
Children's Oncology Group
Medical College of Wisconsin
Children's Oncology Group
Case Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Children's Oncology Group
University of North Carolina, Chapel Hill
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
SWOG Cancer Research Network
Medical College of Wisconsin
Children's Oncology Group
Bristol-Myers Squibb
St. Jude Children's Research Hospital
GOG Foundation
M.D. Anderson Cancer Center
The Hospital for Sick Children
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Takeda
St. Jude Children's Research Hospital
Tufts Medical Center
Children's Oncology Group
Children's Oncology Group
Pierre Fabre Medicament
Dana-Farber Cancer Institute
Hoffmann-La Roche
GOG Foundation
AbbVie
Boehringer Ingelheim
SWOG Cancer Research Network
Hoffmann-La Roche
ETOP IBCSG Partners Foundation
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Children's Oncology Group
Centocor, Inc.